Online citations, reference lists, and bibliographies.
← Back to Search

Cyclosporine A Loaded PLGA Nanoparticles For Dry Eye Disease: In Vitro Characterization Studies

Vijay D. Wagh, Dipak U. Apar
Published 2014 · Materials Science

Cite This
Download PDF
Analyze on Scholarcy
Share
Dry eye disease is a common disease of the tear film caused by decreased tear production or increased evaporation. The objective of this study was to develop and evaluate poly (dl-lactide-co-glycolide) (PLGA) nanoparticles for CsA (CsA) ophthalmic delivery, for the treatment of dry eye disease. Topical CsA is currently the only and safe pharmacologic treatment of severe dry eye symptoms. Nanoparticles (NPs) were prepared by W/O solvent evaporation technique followed by probe sonicator and characterized for various properties such as particle size, entrapment efficiency, zeta potential, in vitro drug release, in vitro permeation studies by Franz diffusion cells, XRD, DSC, SEM, and stability studies. The developed nanosuspension showed a mean particle size in the range from 128 to 253.50 nm before freeze drying and after freeze drying 145.60 to 260.0 nm. The drug entrapment efficiency was from 58.35 to 95.69% and production yield was found between and % in all preparations. The zeta potential of the Eudragit RL containing nanoparticles was positive, that is, 20.3 mV to 34.5 mV. The NPs formulations exhibited a biphasic drug release with initial burst followed by a very slow drug release and total cumulative release up to 24 h ranged from 69.83 to 91.92%. Kinetically, the release profiles of CsA from NPs appeared to fit best with the Higuchi model. The change of surface characteristics of NPs represents a useful approach for improvement of ocular retention and drug availability.
This paper references
The diagnosis andmanagement of dry eye : a twenty - five - year review
M. E. Stern
and P
C. Vauthier-Holtzscherer (1991)
and A
J. Vandervoort (2004)
10.1167/IOVS.05-1373
Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study.
Y. He (2006)
and S
V. D. Wagh (2012)
Investigative Ophthalmology and Visual Science
C. Frey (2010)
10.1080/03639040600975147
Preparation of Azithromycin Nanosuspensions by High Pressure Homogenization and its Physicochemical Characteristics Studies
Dianrui Zhang (2007)
10.1016/J.JCONREL.2004.01.017
Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process.
J. Jaiswal (2004)
and M
J.T.S. Filho (2011)
and E
D. Quintanar-Guerrero (1998)
and T
R. C. Mundargi (2008)
Methodology for the preparation of ultra - dispersed polymer systems
S. Benabbou C. Vauthier-Holtzscherer (1991)
10.1515/9783050077338-026
Y
E. M. S. J. xviii (1824)
10.1517/17425247.2011.610790
Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review
K. Chaturvedi (2011)
10.1016/0378-5173(94)90179-1
Study of the mechanism of interaction of poly(ϵ-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy
P. Calvo (1994)
10.1248/CPB.52.1273
Influence of the homogenisation procedure on the physicochemical properties of PLGA nanoparticles.
J. Vandervoort (2004)
and R
V. B. Patravale (2004)
10.1081/DDC-120014576
Low Molecular Weight Heparin-Loaded Polymeric Nanoparticles: Formulation, Characterization, and Release Characteristics
V. Hoffart (2002)
10.1016/S0928-0987(01)00095-1
Modeling and comparison of dissolution profiles.
P. Costa (2001)
and M
E. Vega (2008)
A. and Q
Neil Genzlinger (2006)
10.1097/00003226-200009000-00009
The Diagnosis and Management of Dry Eye: A Twenty-five–Year Review
S. Pflugfelder (2000)
10.1016/0167-5699(92)90111-J
The mechanism of action of cyclosporin A and FK506.
S. Schreiber (1992)
10.1016/J.IJPHARM.2007.07.041
Adhesion of PLGA or Eudragit/PLGA nanoparticles to Staphylococcus and Pseudomonas.
K. Dillen (2008)
10.1016/J.AJO.2003.10.036
Antiinflammatory therapy for dry eye.
S. Pflugfelder (2004)
10.1016/S0168-3659(00)00339-4
Biodegradable polymeric nanoparticles as drug delivery devices.
K. Soppimath (2001)
10.1016/J.IJPHARM.2005.09.023
Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide.
Ahmed S. Guinedi (2005)
10.2174/156720112803529819
Permeation of PLGA nanoparticles across different in vitro models.
L. Nkabinde (2012)
10.1017/CBO9781139207249.009
I and J
William M. Marsden (2012)
10.3109/03639049809108571
Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers.
D. Quintanar-Guerrero (1998)
Animal Models of Dry Eye Disease- A Review
Vijay D. Wagh (2012)
and M
S. C. Pflugfelder (2000)
10.2174/1389450053765914
Colloidal carriers for ophthalmic drug delivery.
R. Mainardes (2005)
10.1016/b978-0-12-384931-1.00016-7
P
J. Lackie (2013)
10.1515/9783111413426-013
L
Il Liceo (1824)
DRUG DELIVERY AND PHARMACOTHERAPY FOR DRY EYE DISEASE
Vijay D. Wagh (2012)
10.1016/J.EXER.2003.09.003
The role of the lacrimal functional unit in the pathophysiology of dry eye.
M. Stern (2004)
10.1016/j.optm.2009.02.010
Advancements in anti-inflammatory therapy for dry eye syndrome.
E. McCabe (2009)
10.1016/j.colsurfb.2009.03.028
Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres.
J. Araújo (2009)
10.1590/S0100-879X2011007500058
Characterization and analysis of the outcome of adults with acute myeloid leukemia treated in a Brazilian University hospital over three decades.
João Tadeu Damian Souto Filho (2011)
10.1097/01.ico.0000214802.40313.fa
Dysfunctional Tear Syndrome: A Delphi Approach to Treatment Recommendations
A. Behrens (2006)
10.5040/9781474284028.0024
S
A. Kumar (1824)
10.1016/J.IJPHARM.2006.01.041
Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles.
K. Dillen (2006)
10.4103/0974-9233.106384
Nanotechnology Approaches for Ocular Drug Delivery
Qingguo Xu (2013)
10.1016/J.IJPHARM.2004.05.006
pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A.
Jundong Dai (2004)
10.1016/j.jconrel.2011.01.010
Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
P. Aksungur (2011)
10.1016/J.JCONREL.2007.09.013
Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
R. C. Mundargi (2008)
and P
D. Zhang (2007)
and W
K. S. Soppimath (2001)
10.1016/b978-0-12-384931-1.00003-9
C
J. Lackie (2013)
10.1248/CPB.57.657
Particle characterization of poorly water-soluble drugs using a spray freeze drying technique.
M. Kondo (2009)
10.1002/jps.21383
PLGA nanospheres for the ocular delivery of flurbiprofen: drug release and interactions.
E. Vega (2008)
Nanosuspensions: A Promising Drug Delivery Strategy
V. Shinde (2010)
10.1515/9783111576855-012
G
G.V.T.V. Weerasooriya (1824)
10.1211/0022357023691
Nanosuspensions: a promising drug delivery strategy
V. Patravale (2004)
and R
A. S. Guinedi (2005)
and K
M. Kondo (2009)
and S
M. E. Stern (2004)
and E
J. Araújo (2009)
10.1515/9783111697888-004
B
B. A. R. Kernfach (1824)
10.1097/00003226-199007000-00002
Update on topical cyclosporin A. Background, immunology, and pharmacology.
M. Belin (1990)



This paper is referenced by
DEVELOPMENT OF DIOSMIN LOADED EUDRAGIT S100 POLYMERIC NANOPARTICLES: AN INVESTIGATION OF ANTIOXIDANT EFFECT
Khalid Anwer (2015)
10.1016/J.JDDST.2017.06.018
Advances on the formulation of proteins using nanotechnologies
Irene Santalices (2017)
10.1371/journal.pone.0222858
Optimising poly(lactic-co-glycolic acid) microparticle fabrication using a Taguchi orthogonal array design-of-experiment approach
R. Mensah (2019)
10.3390/jcm8081227
Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits
Yu-Kai Kuo (2019)
10.2147/IJN.S244124
Eudragit®-S100 Coated PLGA Nanoparticles for Colon Targeting of Etoricoxib: Optimization and Pharmacokinetic Assessments in Healthy Human Volunteers
Enas El-Maghawry (2020)
10.1016/j.drudis.2016.04.002
Modern approaches to the ocular delivery of cyclosporine A.
P. Agarwal (2016)
on Dry Eye Disease : Diagnosis , Medical Management , Recent Developments , and Future
Suvarna P. Phadatare (2017)
Development and in vitro characterization of niosomal formulations of immunosuppressant model drug.
M. Rehman (2018)
10.1016/j.ijpharm.2015.07.053
Formulation and evaluation of cefuroxim loaded submicron particles for ophthalmic delivery.
Gabriela Andrei (2015)
10.1016/j.heliyon.2020.e04589
Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: in vitro and in vivo evidences
Umesh D. Laddha (2020)
10.1016/J.COLSURFA.2018.07.005
Polyelectrolyte-coated nanocapsules containing cyclosporine A protect neuronal-like cells against oxidative stress-induced cell damage
M. Piotrowski (2018)
10.1016/j.ijpharm.2017.08.069
Colonic delivery of indometacin loaded PGA-co-PDL microparticles coated with Eudragit L100-55 from fast disintegrating tablets.
Hesham M Tawfeek (2017)
10.1155/2015/704946
A Comprehensive Review on Dry Eye Disease: Diagnosis, Medical Management, Recent Developments, and Future Challenges
Suvarna P. Phadatare (2015)
10.3390/pharmaceutics12030253
Assembling Surfactants-Mucoadhesive Polymer Nanomicelles (ASMP-Nano) for Ocular Delivery of Cyclosporine-A
E. Terreni (2020)
10.1016/J.JKSUS.2017.10.004
Morphologies and functionalities of polymeric nanocarriers as chemical tools for drug delivery: A review
I. Venditti (2017)
Semantic Scholar Logo Some data provided by SemanticScholar